Alliance for mRNA Medicines
Become a Member

leon-nanodrugs GmbH

Wolfgang Hofmann, MD

Chief Executive Officer
leon-nanodrugs GmbH
  • R-JET® Technology: one mixer spanning the full platform from R&D to GMP – same design space at every scale.
  • QbD-native, modular mixing hardware for different mRNA-LNP formulations with predictable scale-up.
  • Enabling personalized mRNA medicine: NANOme® closes the GMP manufacturing gap for mRNA/genome-editing therapies with small batch sizes, a small footprint, fast turnaround, and closed-system aseptic processing.
  • Solves scale-up unpredictability: consistent mixing from lab to GMP scale cuts re-optimization and CMC disruption risk – the real cost isn’t lost materials, it’s lost time to process lock, clinical milestones and ultimately product NPV.